PDF herunterladen
Clin Colon Rectal Surg 2009; 22(2): 107-114
DOI: 10.1055/s-0029-1223842
© Thieme Medical Publishers

Rare Anorectal Neoplasms: Gastrointestinal Stromal Tumor, Carcinoid, and Lymphoma

Elizabeth A. Peralta1
  • 1Surgical Oncology, Southern Illinois University School of Medicine, Department of Surgery, Springfield, Illinois
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. Mai 2009 (online)

    Lizenzen und Reprints

ABSTRACT

Several uncommon tumors occur in the anal canal such as gastrointestinal stromal tumors, carcinoids, and lymphoma. Increased clinical experience and advancements in molecular biology have improved the accuracy of pathologic diagnosis and guided treatment recommendations, which the author addresses in this article.

KEYWORDS

Gastrointestinal stromal tumors - carcinoid - lymphoma

REFERENCES

  • 1 Madeleine MM, Newcomer LM Cancer of the anus. National Cancer Institute's's Surveillance, Epidemiology, and End Results Program (SEER). Bethesda, MD; National Cancer Institute 2007: 43
    Google Scholar
  • 2 Kindblom L G, Remotti H E, Aldenborg F, Meis-Kindblom J M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.  Am J Pathol. 1998;  152(5) 1259-1269
    PubMedGoogle Scholar
  • 3 Hatch K F, Blanchard D K, Hatch III G F et al.. Tumors of the rectum and anal canal.  World J Surg. 2000;  24(4) 437-443
    CrossrefPubMedGoogle Scholar
  • 4 Fletcher C D, Berman J J, Corless C et al.. Diagnosis of gastrointestinal stromal tumors: a consensus approach.  Hum Pathol. 2002;  33(5) 459-465
    Google Scholar
  • 5 Nigri G R, Dente M, Valabrega S et al.. Gastrointestinal stromal tumor of the anal canal: an unusual presentation.  World J Surg Oncol. 2007;  5 20
    CrossrefPubMedGoogle Scholar
  • 6 Hirota S, Isozaki K, Moriyama Y et al.. Gain-of-function mutations of C-KIT in human gastrointestinal stromal tumors.  Science. 1998;  279(5350) 577-580
    CrossrefPubMedGoogle Scholar
  • 7 Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.  Arch Pathol Lab Med. 2006;  130(10) 1466-1478
    PubMedGoogle Scholar
  • 8 DeMatteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.  Ann Surg. 2000;  231(1) 51-58
    CrossrefPubMedGoogle Scholar
  • 9 Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin L H, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases.  Am J Surg Pathol. 2001;  25(9) 1121-1133
    CrossrefPubMedGoogle Scholar
  • 10 Eisenberg B L, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.  Ann Surg Oncol. 2004;  11(5) 465-475
    CrossrefPubMedGoogle Scholar
  • 11 Katz S C, DeMatteo R P. Gastrointestinal stromal tumors and leiomyosarcomas.  J Surg Oncol. 2008;  97(4) 350-359
    CrossrefPubMedGoogle Scholar
  • 12 Miettinen M, Sarlomo-Rikala M, Sobin L H. Mesenchymal tumors of muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stromal tumors—a clinicopathologic and immunohistochemical study of eighty-eight cases.  Mod Pathol. 2001;  14(10) 950-956
    CrossrefPubMedGoogle Scholar
  • 13 Hassan I, You Y N, Dozois E J et al.. Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies.  Dis Colon Rectum. 2006;  49(5) 609-615
    CrossrefPubMedGoogle Scholar
  • 14 Tworek J A, Goldblum J R, Weiss S W, Greenson J K, Appelman H D. Stromal tumors of the anorectum: a clinicopathologic study of 22 cases.  Am J Surg Pathol. 1999;  23(8) 946-954
    CrossrefPubMedGoogle Scholar
  • 15 Vorobyov G I, Odaryuk T S, Kapuller L L, Shelygin Y A, Kornyak B S. Surgical treatment of benign, myomatous rectal tumors.  Dis Colon Rectum. 1992;  35(4) 328-331
    CrossrefPubMedGoogle Scholar
  • 16 Demetri G D, Benjamin R S, Blanke C D NCCN Task Force et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines.  J Natl Compr Canc Netw. 2007;  5(Suppl 2) S1-S29, quiz S30
    PubMedGoogle Scholar
  • 17 Levy A D, Remotti H E, Thompson W M, Sobin L H, Miettinen M. Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation.  AJR Am J Roentgenol. 2003;  180(6) 1607-1612
    PubMedGoogle Scholar
  • 18 Dematteo R P, Gold J S, Saran L et al.. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).  Cancer. 2008;  112(3) 608-615
    CrossrefPubMedGoogle Scholar
  • 19 Haque S, Dean P J. Stromal neoplasms of the rectum and anal canal.  Hum Pathol. 1992;  23(7) 762-767
    CrossrefPubMedGoogle Scholar
  • 20 DeMatteo R P, Owzar K, Antonescu C R et al.. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The US. Intergroup Phase II Trial ACOSOG z9000 (Abstract No. 8). Abstract presented at: American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium January 25–27, 2008 Orlando, FL;
    Google Scholar
  • 21 DeMatteo R, Owzar K, Maki R et al.. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III Trial ACOSOG z9001 (Abstract No. 10079). Abstract presented at: 2007 American Society of Clinical Oncology Annual Meeting June 1–5, 2007 Chicago, IL;
    Google Scholar
  • 22 Walsh T H, Mann C V. Smooth muscle neoplasms of the rectum and anal canal.  Br J Surg. 1984;  71(8) 597-599
    CrossrefPubMedGoogle Scholar
  • 23 Changchien C R, Wu M C, Tasi W S et al.. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining.  Dis Colon Rectum. 2004;  47(11) 1922-1929
    CrossrefPubMedGoogle Scholar
  • 24 Li J C, Ng S S, Lo A W, Lee J F, Yiu R Y, Leung K L. Outcome of radical excision of anorectal gastrointestinal stromal tumors in Hong Kong Chinese patients.  Indian J Gastroenterol. 2007;  26(1) 33-35
    PubMedGoogle Scholar
  • 25 Baik S H, Kim N K, Lee C H et al.. Gastrointestinal stromal tumor of the rectum: an analysis of seven cases.  Surg Today. 2007;  37(6) 455-459
    CrossrefPubMedGoogle Scholar
  • 26 Chen C W, Wu C C, Hsiao C W et al.. Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum.  Z Gastroenterol. 2008;  46(8) 760-765
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 27 Demetri G D, von Mehren M, Blanke C D et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.  N Engl J Med. 2002;  347(7) 472-480
    CrossrefPubMedGoogle Scholar
  • 28 Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn J D. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.  Cancer Epidemiol Biomarkers Prev. 2008;  17(8) 2194-2201
    CrossrefPubMedGoogle Scholar
  • 29 Hohenberger P. Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?.  Nat Clin Pract Oncol. 2008;  5(5) 240-241
    CrossrefPubMedGoogle Scholar
  • 30 Rutkowski P, Nowecki Z, Nyckowski P et al.. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.  J Surg Oncol. 2006;  93(4) 304-311
    CrossrefPubMedGoogle Scholar
  • 31 Eisenberg B L, Harris J, Blanke C D et al.. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.  J Surg Oncol. 2009;  99(1) 42-47
    CrossrefPubMedGoogle Scholar
  • 32 Demetri G D, van Oosterom A T, Garrett C R et al.. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.  Lancet. 2006;  368(9544) 1329-1338
    CrossrefPubMedGoogle Scholar
  • 33 Caldarola V T, Jackman R J, Moertel C G, Dockerty M B. Carcinoid tumors of the rectum.  Am J Surg. 1964;  107 844-849
    CrossrefPubMedGoogle Scholar
  • 34 Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases.  Cancer. 2005;  103(8) 1587-1595
    CrossrefPubMedGoogle Scholar
  • 35 Landry C S, Brock G, Scoggins C R, McMasters K M, Martin II R C. A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients.  Surgery. 2008;  144(3) 460-466
    CrossrefPubMedGoogle Scholar
  • 36 Pinchot S N, Holen K, Sippel R S, Chen H. Carcinoid tumors.  Oncologist. 2008;  13(12) 1255-1269
    CrossrefPubMedGoogle Scholar
  • 37 Orloff M J. Carcinoid tumors of the rectum.  Cancer. 1971;  28(1) 175-180
    PubMedGoogle Scholar
  • 38 Oberg K. Carcinoid tumors, the carcinoid syndrome, and related disorders. In: Kronenberg HM Williams Textbook of Endocrinology. Philadelphia, PA; Saunders Elsevier 2008: 1821
    Google Scholar
  • 39 Memon M A, Nelson H. Gastrointestinal carcinoid tumors: current management strategies.  Dis Colon Rectum. 1997;  40(9) 1101-1118
    PubMedGoogle Scholar
  • 40 Jetmore A B, Ray J E, Gathright Jr J B, McMullen K M, Hicks T C, Timmcke A E. Rectal carcinoids: the most frequent carcinoid tumor.  Dis Colon Rectum. 1992;  35(8) 717-725
    CrossrefPubMedGoogle Scholar
  • 41 Fahy B N, Tang L H, Klimstra D et al.. Carcinoid of the rectum risk stratification (CaRRS): a strategy for preoperative outcome assessment.  Ann Surg Oncol. 2007;  14(2) 396-404
    CrossrefPubMedGoogle Scholar
  • 42 Kwaan M R, Goldberg J E, Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy.  Arch Surg. 2008;  143(5) 471-475
    CrossrefPubMedGoogle Scholar
  • 43 Koura A N, Giacco G G, Curley S A, Skibber J M, Feig B W, Ellis L M. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival.  Cancer. 1997;  79(7) 1294-1298
    CrossrefPubMedGoogle Scholar
  • 44 Shepherd N A, Hall P A, Coates P J, Levison D A. Primary malignant lymphoma of the colon and rectum. A histopathological and immunohistochemical analysis of 45 cases with clinicopathological correlations.  Histopathology. 1988;  12(3) 235-252
    PubMedGoogle Scholar
  • 45 Ioachim H L, Antonescu C, Giancotti F, Dorsett B, Weinstein M A. EBV-associated anorectal lymphomas in patients with acquired immune deficiency syndrome.  Am J Surg Pathol. 1997;  21(9) 997-1006
    CrossrefPubMedGoogle Scholar
  • 46 Diamond C, Taylor T H, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.  Cancer. 2006;  106(1) 128-135
    CrossrefPubMedGoogle Scholar
  • 47 The N CCN. Clinical Practice Guidelines in Oncology™ Non-Hodgkin Lymphoma (Version I. 2009). Fort Washington, PA; National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org Accessed February 15, 2009
    Google Scholar

Elizabeth A PeraltaM.D. 

Surgical Oncology, Southern Illinois University School of Medicine, Department of Surgery

701 N. First St., P.O. Box 19638, Springfield, IL 62794

eMail: eperalta@siumed.edu

      >